Lv2
148 积分 2021-07-14 加入
Surrogate endpoints in clinical trials: Definition and operational criteria
1天前
已完结
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
15天前
已完结
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
15天前
已完结
Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss
27天前
已完结
The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?
1个月前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
Handling time‐varying treatments in observational studies: A scoping review and recommendations
5个月前
已完结
Automated segmentation of brain metastases with deep learning: a multi-center, randomized crossover, multi-reader evaluation study
6个月前
已完结
Statistical methods to control for confounders in rare disease settings that use external control
6个月前
已完结
皖公网安备34019202002308
